View ValuationSharps Technology 将来の成長Future 基準チェック /06現在、 Sharps Technologyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 25+ 1 more updateSharps Technology Inc. Appoints Arthur Levine as Interim Chief Financial Officer, Effective February 17, 2026Sharps Technology Inc. appointed Arthur Levine as interim Chief Financial Officer for an initial term of three months, effective February 17, 2026. Arthur Levine, age 68, has provided fractional and interim consulting services from 2023 to 2026 to companies in various industries at various stages of growth. From March 2021 to July 2023, Mr. Levine served as the Chief Financial Officer of NextNRG, Inc. (f.k.a EzFill Holdings), a mobile fueling company. From 2014 to 2020, Mr. Levine served as the Chief Financial Officer of Sensus Healthcare, a medical device company. Mr. Levine received his Bachelor of Science degree from The Wharton School of the University of Pennsylvania and is a Certified Public Accountant. Sharps Technology Inc. entered into its standard form of indemnification agreement, effective February 17, 2026, with Mr. Levine, which requires the Company to indemnify Mr. Levine against certain liabilities that may arise as result of his status or service as the interim Chief Financial Officer. The Company has initiated its search for a Chief Financial Officer. The Company expects to retain the services of Mr. Levine until such time its search for a permanent replacement Chief Financial Officer is successfully concluded.お知らせ • Jan 13Sharps Technology and Coinbase Expand Relationship with Launch of Institutional-Grade Solana ValidatorSharps Technology, Inc. announced the expansion of its relationship with Coinbase Institutional, through the launch of a jointly supported institutional-grade validator on the Solana network. The STSS Validator, operated by Coinbase and built on Coinbase Institutional's market-proven infrastructure stack, represents a meaningful shift for the company as it moves from a Solana treasury participant to a direct contributor to the security and decentralization of the network. Under this expanded initiative, STSS will delegate a portion of its SOL treasury holdings, currently more than 2 million SOL, to its newly established Coinbase-operated validator. The expanded relationship brings together Coinbase's institutional-grade infrastructure, security standards, and proven validator operations, to ensure high uptime, operational rigor, and long-term reliability. This expansion builds on the company's existing relationship with Coinbase Institutional, Through which STSS leverages Coinbase's custody, OTC, and operational infrastructure as part of its broader digital asset treasury strategy. With this validator launch, STSS becomes one of the first U.S.-listed companies to evolve from a treasury-only approach to an active infrastructure participant in blockchain development.Seeking Alpha • Oct 05Sharps Technology: From Medical Devices To Solana TreasurySummary Sharps Technology pivoted into a crypto treasury model with a significant Solana allocation, now holding roughly the same SOL amount as peers DFDV and Upexi, both around 2 million SOL. Sharps’ entry into SOL occurred around the $200 price level, below its $293 all-time high, positioning it well for upside if SOL rallies. Sharps’ core safety syringe business continues to face low revenue and inventory buildup, with Q2 revenue at $223k. Q2 net income of $5.5 million was mainly driven by a non-cash fair value gain on warrants remeasured under ASC 815. Read the full article on Seeking Alphaお知らせ • Oct 02Sharps Technology, Inc. (NasdaqCM:STSS) announces an Equity Buyback for $100 million worth of its shares.Sharps Technology, Inc. (NasdaqCM:STSS) announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its shares.お知らせ • Sep 02Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $236.605575 million.Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $236.605575 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Aug 29Sharps Technology, Inc. announced that it has received $400 million in funding from a group of investorsOn August 28, 2025, the Sharps Technology, Inc. closed the transaction for the proceeds of $400 million. The transaction involves participation of FalconX, Phoenix Digital, Bastion Trading, RockawayX, Syncracy, Republic Digital, Arche Capital, Arrington Capital, Hypersphere, Quantstamp, FinTech Collective, CoinList Alpha, Primitive Ventures, Avenir Group, Luca Netz, Cube, and Saba Capital, and other investors.お知らせ • Jul 06Sharps Technology, Inc., Annual General Meeting, Aug 19, 2025Sharps Technology, Inc., Annual General Meeting, Aug 19, 2025.お知らせ • Apr 05Nasdaq Notifies Sharps Technology Regarding Non-Compliance with the $2,500,000 Stockholders’ Equity RequirementOn April 3, 2025, Sharps Technology Inc. (the ‘Company’), was notified by the staff (the ‘Staff’) of The Nasdaq Stock Market, LLC (‘Nasdaq’) that it was not in compliance with the $2,500,000 stockholders’ equity requirement for continued listing (the ‘Rule’) on The Nasdaq Capital Market. As reported in our Form 10-K for the fiscal year ended December 31, 2024, we reported stockholders’ equity of $1,996,129, and as of today, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. As the Company is already in the hearings process due to non-compliance with the minimum bid price requirement as previously reported in the Form 8-K filed on March 14, 2025, this will be treated as an additional and separate basis for delisting. The Company will present its views and its plans to regain compliance with respect to this additional deficiency at its Nasdaq hearing. There can be no assurance that the Company will be able to evidence compliance with the stockholders’ equity Rule or any other applicable requirements for continued listing on The Nasdaq Capital Market prior to the hearing. In the interim, the Company’s common stock and warrants will remain listed on Nasdaq under its existing symbols, ‘STSS’ and ‘STSSW’ while it awaits the hearing and Panel decision.お知らせ • Mar 15Sharps Technology Receives Non-Compliance letter from Nasdaq Regarding Minimum Bid Price RequirementAs previously reported on October 16, 2024, the Company effected a 1-for-22 reverse stock split. In connection with same, the Staff (as defined below) determined that the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, and as a result, does not comply with Nasdaq Listing Rule 5550(a)(2). As such, on March 12, 2025, Sharps Technology, Inc. (the Company"), was notified by the staff (the Staff") of The Nasdaq Stock Market, LLC (Nasdaq") that it was not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market as the bid price of its securities had closed at less than $1.00 per share over the previous 30 consecutive business days. Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the rule. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period due to the fact that the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Company's securities will be delisted from the Nasdaq Capital Market unless the Company requests a hearing and appeals Nasdaq's determination. Accordingly, the Company will be timely filing a hearing request before the deadline which will automatically stay the delisting and suspension of the Company's securities pending the decision of the Nasdaq Hearings Panel (the Panel"). At the hearing, the Company intends to present its views and its plans to regain compliance with the minimum bid price rule to the Panel. There can be no assurance that the Company will be able to evidence compliance with the minimum bid price rules or any other applicable requirements for continued listing on The Nasdaq Capital Market prior to the hearing. In the interim, the Company expects its common stock and warrants will remain listed on Nasdaq under its existing symbols, STSS" and STSSW" while it awaits the hearing.お知らせ • Jan 29Sharps Technology, Inc. has completed a Composite Units Offering in the amount of $20 million.Sharps Technology, Inc. has completed a Composite Units Offering in the amount of $20 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 14,285,714 Price\Range: $1.4 Discount Per Security: $0.098 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 14,285,714 Price\Range: $1.3999 Discount Per Security: $0.9799お知らせ • Nov 11Sharps Technology, Inc., Annual General Meeting, Dec 19, 2024Sharps Technology, Inc., Annual General Meeting, Dec 19, 2024.お知らせ • Sep 12Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ MeetingSharps Technology, Inc. announced that the Company has secured approval from The Nasdaq Stock Market (‘Nasdaq’ or the ‘Exchange’) to maintain its listing, subject to conditions outlined the following. On September 9, 2024, Sharps Technology received a Determination Letter from Nasdaq confirming the Company's continued listing on the Exchange. This follows the August 13, 2024, hearing with the Nasdaq Hearings Panel, where the Company presented its compliance plan. At the August hearing, the Company’s senior management and outside counsel outlined its compliance plan to address a bid price deficiency. Previously, the Company had been granted an extension to resolve the deficiency, wherein the Company agreed to conduct a reverse split and obtained shareholder approval at a ratio of up to one share for eight. After obtaining shareholder approval, anew Exchange rule was proposed that would subject a company with a bid price deficiency to immediate delisting if the same company had experienced a bid price deficiency in the previous 12 months. As a result of this proposed rule, the Company determined to seek shareholder approval for a reverse split at a higher ratio to improve its chances of maintaining compliance with the bid price rule on a long-term basis. The Nasdaq Hearings Panel has granted the Company a brief exception to complete a reverse split and cure its bid price deficiency. Accordingly, the Company expects to complete a reverse stock split and regain compliance with the bid price rule within the exception period granted by the Panel.New Risk • Aug 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$7.20m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (145% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.20m market cap).お知らせ • Jul 17Sharps Technology, Inc. Receive Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)On July 12, 2023, The Nasdaq Stock Market LLC (Nasdaq") notified Sharps Technology, Inc. (the Company") that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, the Company was no longer in compliance with Nasdaq Listing Rule 5550(a)(2) (the Nasdaq Rule"). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until January 8, 2024, to regain compliance with the Rule. Subsequently, on January 16, 2024, the Company was provided an additional 180 calendar day compliance period, or until July 8, 2024, to demonstrate compliance. Pursuant to Nasdaq's letter on July 9, 2024, the Company has not regained compliance with Listing Rule 5550(a)(2). Accordingly, its securities will be delisted from the Nasdaq Capital Market unless the Company requests a hearing and appeals Nasdaq's determination by July 16, 2024, the trading of the Company's common stock and warrants will be suspended at the opening of business on July 18, 2024. If the Company does not request a hearing, Nasdaq will complete the delisting by filing a Form 25-NSE Notification of Delisting with the U.S. Securities and Exchange Commission (the SEC") after applicable appeal periods have lapsed. The Company will be filing a hearing request before the deadline. In the interim, the Company expects its common stock and warrants will remain listed on NASDAQ under its existing symbols, STSS" and STSW" while it awaits the hearing.お知らせ • Jul 10Sharps Technology, Inc. announced a financing transactionSharps Technology, Inc. announced a private placement that it will issue common shares of the company to receive funding on July 9, 2024.New Risk • Jun 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$19.6m market cap).New Risk • May 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 43% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$3.36m market cap). Minor Risk Shareholders have been diluted in the past year (34% increase in shares outstanding).お知らせ • May 22Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $14.1 million.Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $14.1 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 47,000,000 Price\Range: $0.3 Discount Per Security: $0.021New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$5.09m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$4.4m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Jan 20Listing Qualifications Department of the Nasdaq Stock Market LLC Determines Sharps Technology, Inc. Is Eligible for an Additional 180 Calendar Day Period, or Until July 8, 2024, to Regain ComplianceAs disclosed in a Current Report filed on Form 8-K on July 16, 2023, Sharps Technology, Inc. (the “Company”) had received a notice (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) because it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days dated May 26, 2023 to July 11, 2023. The Rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten (10) consecutive business days, the Staff will provide written confirmation of compliance and this matter will be closed. On January 16, 2023, the Staff determined that the Company is eligible for an additional 180 calendar day period, or until July 8, 2024, to regain compliance. The Staff’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, the Staff will provide notice that its securities will be subject to delisting. The Company will continue to monitor the closing bid price of its Common Stock and will consider its available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement within the allotted compliance period.New Risk • Nov 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$8.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.8m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$6.34m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$4.4m net loss next year).お知らせ • Nov 09Sharps Technology, Inc., Annual General Meeting, Dec 19, 2023Sharps Technology, Inc., Annual General Meeting, Dec 19, 2023, at 10:00 US Eastern Standard Time. Agenda: To consider and elect six directors, to serve until the Company’s 2024 annual meeting of stockholders or until their successors are duly elected and qualified; to approve, for purposes of complying with the provisions of those certain Securities Purchase Agreements dated September 27, 2023 (the SPA), the reduction of the potential minimum exercise price of warrants issued pursuant to the SPA from $0.64 to $0.0001, which is the par value of the common stock of the Company; to ratify the appointment of Manning Elliott LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; to approve proposed amendments to the Sharps Technology, Inc. 2023 Equity Incentive Plan, in substantially the form attached to the proxy statement as Annex A; and to consider other matters.New Risk • Oct 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 66% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$8.47m market cap).お知らせ • Sep 28Sharps Technology, Inc. announced that it expects to receive $5.6 million in fundingSharps Technology, Inc. announced a private placement of units at a price of $0.80 per unit for gross proceeds of $5,600,000 on September 27, 2023. The units consist of pre-funded warrants to purchase up to 2,581,479 common shares and common warrants to purchase 8,750,000 common shares at an exercise price of $0.64 per share. The exercise price per pre-funded warrant is $0.001 per share. The private placement warrants will be exercisable immediately subject to registration and will have a 5.5-year term from the initial exercise date. The transactions are expected to close on or about September 29, 2023, subject to the satisfaction of customary closing conditions.お知らせ • Jul 16Sharps Technology Receives a Notice from the Staff of the Listing Qualifications Department of the Nasdaq Stock MarketOn July 12, 2023, Sharps Technology, Inc. received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days dated May 26, 2023 to July 11, 2023. The Rules provide the company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, the Staff will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the minimum bid price requirement within the 180 day automatic cure period, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, apart from the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Staff will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff will provide notice that its securities will be subject to delisting. The Company will continue to monitor the closing bid price of its Common Stock and will consider its available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement within the allotted compliance period.お知らせ • Jul 13Sharps Technology Appoints Ben Scheu as Senior Director of SalesSharps Technology, Inc. announced the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market. Mr. Scheu has held executive leadership positions in prominent healthcare companies and has demonstrated his ability to drive sales growth and develop effective commercial strategies. Prior to joining Sharps, Mr. Scheu served as President and CEO of Centor Inc., a pharmaceutical packaging manufacturing division of Gerresheimer with a complete line of regulatory compliant prescription containers for medication dispensing, packaging for robotic automation and standard and custom imprinted closures. At Centor, he oversaw significant revenue growth that led their company to achieve a market leading position in the prescription container and medication dispensing product segment. Additionally, Mr. Scheu served as COO of The Waddington Group, a division of Newell Brands (an $850 million per year disposable packaging manufacturer), President of B+H North America (a $400 million per year division of the AptarGroup), President of Rigid Closed Top (an ~$1 billion per year division of Berry Plastics Corporation), and executive sales and marketing roles at leading specialty market corporations. Mr. Scheu will be instrumental in leading Sharps’ marketing initiatives as the Company advances from research and development to commercial revenue. His initial focus will be leading sales efforts around Sharps’ commercial-ready Securegard®, a disposable smart safety syringe product offering with multiple configurations. Mr. Scheu will lead the efforts around commercialization and contracts with customers within the retail pharmacy space to support the efforts around the introduction of Sharps’ technology to healthcare customers, which include hospital networks. Sharps recently announced a qualification agreement with a major medical device company for its smart safety syringe technology that could drive increased commercial revenue in 2023. The agreement will begin with the 1mL and 3mL Securegard® product line and will be followed by Sologard® Luer lock syringes for larger volume drug applications. The qualification agreement will allow for the opportunity to create secondary sales agreements with additional key hospital networks, which Mr. Scheu will oversee. In conjunction with the vial-draw product launch, Sharps is also preparing for the commercialization of its next-generation polymer-based prefilled syringe systems, which will be the Company’s future growth driver. Technical and commercial resources will be added to Mr. Scheu’s prefilled product team, and Sharps will begin manufacturing from the Inject-EZ facility in Columbia, South Carolina. Through Mr. Scheu’s deep expertise in plastics operations and sales, he will play an integral role in supporting the partnership with Nephron Pharmaceuticals.New Risk • Jun 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.87m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.87m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding).お知らせ • Feb 07Sharps Technology, Inc. announced that it has received $3.8 million in fundingOn February 6, 2023, Sharps Technology, Inc. closed the transaction.お知らせ • Feb 02Sharps Technology, Inc. announced that it expects to receive $3.8 million in fundingSharps Technology, Inc. announced that it has raised $3.8 million. The Company will issue 2,248,521 units and pre-funded units at a purchase price of $1.69 per unit priced at-the-market under Nasdaq rules.The pre-funded units will be sold at the same price less the pre-funded warrant exercise price of $0.001. Each unit and pre-funded unit consist of one share of common stock (or pre-funded warrant) and one non-tradable warrant exercisable for one share of common stock at a price of $1.56. The warrants have a term of five years from the issuance date. Gross proceeds were $3.8 million before deducting fees to the placement agent and other offering expenses payable by the Company. The transaction is expected to close on or about February 3, 2023お知らせ • Feb 01Sharps Technology, Inc. Ships First Containers of Safety Syringes to Nephron Pharmaceuticals for CommercializationSharps Technology, Inc. announced the first shipments of product from its wholly owned manufacturing facility in Hungary to Nephron Pharmaceuticals to advance the Company's first commercial operations. Securegard is the first product that will be available to the market through the Company's collaboration with Nephron and will be introduced through Nephron’s network of more than 3,000 customers. Securegard is a vial draw product with innovative product features for safety, ultra-low waste and non-reuse that has been approved by the Food and Drug Administration (FDA), the World Health Organization (WHO), and received a CE Mark, facilitating global sales. Initial shipments will total 1.3 million 1-mililiter (1mL) units by February and will increase with additional volume and product configurations as sales commence.お知らせ • Jan 12Sharps Technology Inc. to Introduces New Specialized Prefillable Syringe Systems in 2023Sharps Technology, Inc. announces the advancement of the Company's specialized prefillable syringe ("PFS") system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina. Sharps' specialized product pipeline and market strategy will include a broad range of sizes, silicon free systems that address contamination issues for the broader healthcare market, dual chamber systems that improve drug shelf life while reducing unnecessary packaging, and customized solutions for systems that serve the growing autoinjector segment. Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina. Initial demand will be supported by manufacturing capacity of 20+ million units, with additional capacities that can be scaled by 2025 with an additional 100 million units annually. Products will be manufactured utilizing Injection molding technologies with highly automated assembly lines. The products will be sterilized using an ecofriendly clean sterilization option easily adaptable for the pharmaceutical market. Sharps' PFS systems will utilize ISO Standard Nest and Tubs that will be compatible with existing fill-finish technologies to provide a drop-in solution for the industry.Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jul 15Sharps Technology, Inc. (NasdaqCM:STSS) completed the acquisition of Safegard Medical (Hungary) Kft. from Numan Holding Ltd.Sharps Technology, Inc. (NasdaqCM:STSS) agreed to acquire Safegard Medical (Hungary) Kft. from Numan Holding Ltd. for $2.5 million on July 8, 2022. The purchase price of $2.5 million was released to Numan. Sharps Technology previously issued 28,571 shares of common stock and 35,714 warrants to purchase common stock at $7.00 per share to Numan. The Acquisition consisted primarily of Safegard’s syringe manufacturing facility in Hungary and the land on which it is located, as well as certain equipment in the facility. Sharps Technology, Inc. (NasdaqCM:STSS) completed the acquisition of Safegard Medical (Hungary) Kft. from Numan Holding Ltd. on July 14, 2022.Board Change • Jun 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • May 13Independent Non-Executive Director recently bought US$140k worth of stockOn the 9th of May, Timothy Ruemler bought around 112k shares on-market at roughly US$1.25 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$263k more in shares than they have sold in the last 12 months.Board Change • May 02High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 20Brenda Baird Simpson and Jason Monroe Elects to Sharps Technology, Inc.'s Board of DirectorsOn April 15, 2022, Brenda Baird Simpson and Jason Monroe were elected to the Sharps Technology, Inc.'s board of directors. Ms. Simpson will serve on the audit committee of the Company’s board of directors, and Mr. Monroe will serve on the audit, compensation and nominating committees.お知らせ • Apr 16Sharps Technology, Inc. has completed an IPO in the amount of $15.9375 million.Sharps Technology, Inc. has completed an IPO in the amount of $15.9375 million. Security Name: Common Units Security Type: Equity/Derivative Unit Securities Offered: 3,750,000 Price\Range: $4.25 Discount Per Security: $0.34 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sharps Technology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:STSS - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20260-359-17-17N/A12/31/20250-270-17-17N/A9/30/20250-104-17-14N/A6/30/20250-1-10-8N/A3/31/2025N/A-6-8-7N/A12/31/2024N/A-5-7-7N/A9/30/2024N/A-8-8-8N/A6/30/2024N/A-8-8-8N/A3/31/2024N/A-9-9-8N/A12/31/2023N/A-10-9-9N/A9/30/2023N/A-8-11-8N/A6/30/2023N/A-8-10-7N/A3/31/2023N/A-5-11-7N/A12/31/2022N/A-5-10-6N/A9/30/2022N/A-5-7-6N/A6/30/2022N/A-4-6-5N/A3/31/2022N/A-6-5-4N/A12/31/2021N/A-5-5-3N/A9/30/2021N/A-4-5-3N/A12/31/2020N/A-2-2-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: STSSの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: STSSの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: STSSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: STSSの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: STSSの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: STSSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 21:40終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sharps Technology, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関David BoucheyAegis Capital Corporation
お知らせ • Feb 25+ 1 more updateSharps Technology Inc. Appoints Arthur Levine as Interim Chief Financial Officer, Effective February 17, 2026Sharps Technology Inc. appointed Arthur Levine as interim Chief Financial Officer for an initial term of three months, effective February 17, 2026. Arthur Levine, age 68, has provided fractional and interim consulting services from 2023 to 2026 to companies in various industries at various stages of growth. From March 2021 to July 2023, Mr. Levine served as the Chief Financial Officer of NextNRG, Inc. (f.k.a EzFill Holdings), a mobile fueling company. From 2014 to 2020, Mr. Levine served as the Chief Financial Officer of Sensus Healthcare, a medical device company. Mr. Levine received his Bachelor of Science degree from The Wharton School of the University of Pennsylvania and is a Certified Public Accountant. Sharps Technology Inc. entered into its standard form of indemnification agreement, effective February 17, 2026, with Mr. Levine, which requires the Company to indemnify Mr. Levine against certain liabilities that may arise as result of his status or service as the interim Chief Financial Officer. The Company has initiated its search for a Chief Financial Officer. The Company expects to retain the services of Mr. Levine until such time its search for a permanent replacement Chief Financial Officer is successfully concluded.
お知らせ • Jan 13Sharps Technology and Coinbase Expand Relationship with Launch of Institutional-Grade Solana ValidatorSharps Technology, Inc. announced the expansion of its relationship with Coinbase Institutional, through the launch of a jointly supported institutional-grade validator on the Solana network. The STSS Validator, operated by Coinbase and built on Coinbase Institutional's market-proven infrastructure stack, represents a meaningful shift for the company as it moves from a Solana treasury participant to a direct contributor to the security and decentralization of the network. Under this expanded initiative, STSS will delegate a portion of its SOL treasury holdings, currently more than 2 million SOL, to its newly established Coinbase-operated validator. The expanded relationship brings together Coinbase's institutional-grade infrastructure, security standards, and proven validator operations, to ensure high uptime, operational rigor, and long-term reliability. This expansion builds on the company's existing relationship with Coinbase Institutional, Through which STSS leverages Coinbase's custody, OTC, and operational infrastructure as part of its broader digital asset treasury strategy. With this validator launch, STSS becomes one of the first U.S.-listed companies to evolve from a treasury-only approach to an active infrastructure participant in blockchain development.
Seeking Alpha • Oct 05Sharps Technology: From Medical Devices To Solana TreasurySummary Sharps Technology pivoted into a crypto treasury model with a significant Solana allocation, now holding roughly the same SOL amount as peers DFDV and Upexi, both around 2 million SOL. Sharps’ entry into SOL occurred around the $200 price level, below its $293 all-time high, positioning it well for upside if SOL rallies. Sharps’ core safety syringe business continues to face low revenue and inventory buildup, with Q2 revenue at $223k. Q2 net income of $5.5 million was mainly driven by a non-cash fair value gain on warrants remeasured under ASC 815. Read the full article on Seeking Alpha
お知らせ • Oct 02Sharps Technology, Inc. (NasdaqCM:STSS) announces an Equity Buyback for $100 million worth of its shares.Sharps Technology, Inc. (NasdaqCM:STSS) announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its shares.
お知らせ • Sep 02Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $236.605575 million.Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $236.605575 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Aug 29Sharps Technology, Inc. announced that it has received $400 million in funding from a group of investorsOn August 28, 2025, the Sharps Technology, Inc. closed the transaction for the proceeds of $400 million. The transaction involves participation of FalconX, Phoenix Digital, Bastion Trading, RockawayX, Syncracy, Republic Digital, Arche Capital, Arrington Capital, Hypersphere, Quantstamp, FinTech Collective, CoinList Alpha, Primitive Ventures, Avenir Group, Luca Netz, Cube, and Saba Capital, and other investors.
お知らせ • Jul 06Sharps Technology, Inc., Annual General Meeting, Aug 19, 2025Sharps Technology, Inc., Annual General Meeting, Aug 19, 2025.
お知らせ • Apr 05Nasdaq Notifies Sharps Technology Regarding Non-Compliance with the $2,500,000 Stockholders’ Equity RequirementOn April 3, 2025, Sharps Technology Inc. (the ‘Company’), was notified by the staff (the ‘Staff’) of The Nasdaq Stock Market, LLC (‘Nasdaq’) that it was not in compliance with the $2,500,000 stockholders’ equity requirement for continued listing (the ‘Rule’) on The Nasdaq Capital Market. As reported in our Form 10-K for the fiscal year ended December 31, 2024, we reported stockholders’ equity of $1,996,129, and as of today, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. As the Company is already in the hearings process due to non-compliance with the minimum bid price requirement as previously reported in the Form 8-K filed on March 14, 2025, this will be treated as an additional and separate basis for delisting. The Company will present its views and its plans to regain compliance with respect to this additional deficiency at its Nasdaq hearing. There can be no assurance that the Company will be able to evidence compliance with the stockholders’ equity Rule or any other applicable requirements for continued listing on The Nasdaq Capital Market prior to the hearing. In the interim, the Company’s common stock and warrants will remain listed on Nasdaq under its existing symbols, ‘STSS’ and ‘STSSW’ while it awaits the hearing and Panel decision.
お知らせ • Mar 15Sharps Technology Receives Non-Compliance letter from Nasdaq Regarding Minimum Bid Price RequirementAs previously reported on October 16, 2024, the Company effected a 1-for-22 reverse stock split. In connection with same, the Staff (as defined below) determined that the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, and as a result, does not comply with Nasdaq Listing Rule 5550(a)(2). As such, on March 12, 2025, Sharps Technology, Inc. (the Company"), was notified by the staff (the Staff") of The Nasdaq Stock Market, LLC (Nasdaq") that it was not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market as the bid price of its securities had closed at less than $1.00 per share over the previous 30 consecutive business days. Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the rule. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period due to the fact that the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Company's securities will be delisted from the Nasdaq Capital Market unless the Company requests a hearing and appeals Nasdaq's determination. Accordingly, the Company will be timely filing a hearing request before the deadline which will automatically stay the delisting and suspension of the Company's securities pending the decision of the Nasdaq Hearings Panel (the Panel"). At the hearing, the Company intends to present its views and its plans to regain compliance with the minimum bid price rule to the Panel. There can be no assurance that the Company will be able to evidence compliance with the minimum bid price rules or any other applicable requirements for continued listing on The Nasdaq Capital Market prior to the hearing. In the interim, the Company expects its common stock and warrants will remain listed on Nasdaq under its existing symbols, STSS" and STSSW" while it awaits the hearing.
お知らせ • Jan 29Sharps Technology, Inc. has completed a Composite Units Offering in the amount of $20 million.Sharps Technology, Inc. has completed a Composite Units Offering in the amount of $20 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 14,285,714 Price\Range: $1.4 Discount Per Security: $0.098 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 14,285,714 Price\Range: $1.3999 Discount Per Security: $0.9799
お知らせ • Nov 11Sharps Technology, Inc., Annual General Meeting, Dec 19, 2024Sharps Technology, Inc., Annual General Meeting, Dec 19, 2024.
お知らせ • Sep 12Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ MeetingSharps Technology, Inc. announced that the Company has secured approval from The Nasdaq Stock Market (‘Nasdaq’ or the ‘Exchange’) to maintain its listing, subject to conditions outlined the following. On September 9, 2024, Sharps Technology received a Determination Letter from Nasdaq confirming the Company's continued listing on the Exchange. This follows the August 13, 2024, hearing with the Nasdaq Hearings Panel, where the Company presented its compliance plan. At the August hearing, the Company’s senior management and outside counsel outlined its compliance plan to address a bid price deficiency. Previously, the Company had been granted an extension to resolve the deficiency, wherein the Company agreed to conduct a reverse split and obtained shareholder approval at a ratio of up to one share for eight. After obtaining shareholder approval, anew Exchange rule was proposed that would subject a company with a bid price deficiency to immediate delisting if the same company had experienced a bid price deficiency in the previous 12 months. As a result of this proposed rule, the Company determined to seek shareholder approval for a reverse split at a higher ratio to improve its chances of maintaining compliance with the bid price rule on a long-term basis. The Nasdaq Hearings Panel has granted the Company a brief exception to complete a reverse split and cure its bid price deficiency. Accordingly, the Company expects to complete a reverse stock split and regain compliance with the bid price rule within the exception period granted by the Panel.
New Risk • Aug 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$7.20m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (145% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.20m market cap).
お知らせ • Jul 17Sharps Technology, Inc. Receive Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)On July 12, 2023, The Nasdaq Stock Market LLC (Nasdaq") notified Sharps Technology, Inc. (the Company") that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, the Company was no longer in compliance with Nasdaq Listing Rule 5550(a)(2) (the Nasdaq Rule"). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until January 8, 2024, to regain compliance with the Rule. Subsequently, on January 16, 2024, the Company was provided an additional 180 calendar day compliance period, or until July 8, 2024, to demonstrate compliance. Pursuant to Nasdaq's letter on July 9, 2024, the Company has not regained compliance with Listing Rule 5550(a)(2). Accordingly, its securities will be delisted from the Nasdaq Capital Market unless the Company requests a hearing and appeals Nasdaq's determination by July 16, 2024, the trading of the Company's common stock and warrants will be suspended at the opening of business on July 18, 2024. If the Company does not request a hearing, Nasdaq will complete the delisting by filing a Form 25-NSE Notification of Delisting with the U.S. Securities and Exchange Commission (the SEC") after applicable appeal periods have lapsed. The Company will be filing a hearing request before the deadline. In the interim, the Company expects its common stock and warrants will remain listed on NASDAQ under its existing symbols, STSS" and STSW" while it awaits the hearing.
お知らせ • Jul 10Sharps Technology, Inc. announced a financing transactionSharps Technology, Inc. announced a private placement that it will issue common shares of the company to receive funding on July 9, 2024.
New Risk • Jun 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$19.6m market cap).
New Risk • May 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 43% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$3.36m market cap). Minor Risk Shareholders have been diluted in the past year (34% increase in shares outstanding).
お知らせ • May 22Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $14.1 million.Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $14.1 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 47,000,000 Price\Range: $0.3 Discount Per Security: $0.021
New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$5.09m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$4.4m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Jan 20Listing Qualifications Department of the Nasdaq Stock Market LLC Determines Sharps Technology, Inc. Is Eligible for an Additional 180 Calendar Day Period, or Until July 8, 2024, to Regain ComplianceAs disclosed in a Current Report filed on Form 8-K on July 16, 2023, Sharps Technology, Inc. (the “Company”) had received a notice (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) because it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days dated May 26, 2023 to July 11, 2023. The Rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten (10) consecutive business days, the Staff will provide written confirmation of compliance and this matter will be closed. On January 16, 2023, the Staff determined that the Company is eligible for an additional 180 calendar day period, or until July 8, 2024, to regain compliance. The Staff’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, the Staff will provide notice that its securities will be subject to delisting. The Company will continue to monitor the closing bid price of its Common Stock and will consider its available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement within the allotted compliance period.
New Risk • Nov 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$8.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.8m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$6.34m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$4.4m net loss next year).
お知らせ • Nov 09Sharps Technology, Inc., Annual General Meeting, Dec 19, 2023Sharps Technology, Inc., Annual General Meeting, Dec 19, 2023, at 10:00 US Eastern Standard Time. Agenda: To consider and elect six directors, to serve until the Company’s 2024 annual meeting of stockholders or until their successors are duly elected and qualified; to approve, for purposes of complying with the provisions of those certain Securities Purchase Agreements dated September 27, 2023 (the SPA), the reduction of the potential minimum exercise price of warrants issued pursuant to the SPA from $0.64 to $0.0001, which is the par value of the common stock of the Company; to ratify the appointment of Manning Elliott LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; to approve proposed amendments to the Sharps Technology, Inc. 2023 Equity Incentive Plan, in substantially the form attached to the proxy statement as Annex A; and to consider other matters.
New Risk • Oct 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 66% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$8.47m market cap).
お知らせ • Sep 28Sharps Technology, Inc. announced that it expects to receive $5.6 million in fundingSharps Technology, Inc. announced a private placement of units at a price of $0.80 per unit for gross proceeds of $5,600,000 on September 27, 2023. The units consist of pre-funded warrants to purchase up to 2,581,479 common shares and common warrants to purchase 8,750,000 common shares at an exercise price of $0.64 per share. The exercise price per pre-funded warrant is $0.001 per share. The private placement warrants will be exercisable immediately subject to registration and will have a 5.5-year term from the initial exercise date. The transactions are expected to close on or about September 29, 2023, subject to the satisfaction of customary closing conditions.
お知らせ • Jul 16Sharps Technology Receives a Notice from the Staff of the Listing Qualifications Department of the Nasdaq Stock MarketOn July 12, 2023, Sharps Technology, Inc. received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days dated May 26, 2023 to July 11, 2023. The Rules provide the company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, the Staff will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the minimum bid price requirement within the 180 day automatic cure period, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, apart from the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Staff will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff will provide notice that its securities will be subject to delisting. The Company will continue to monitor the closing bid price of its Common Stock and will consider its available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement within the allotted compliance period.
お知らせ • Jul 13Sharps Technology Appoints Ben Scheu as Senior Director of SalesSharps Technology, Inc. announced the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market. Mr. Scheu has held executive leadership positions in prominent healthcare companies and has demonstrated his ability to drive sales growth and develop effective commercial strategies. Prior to joining Sharps, Mr. Scheu served as President and CEO of Centor Inc., a pharmaceutical packaging manufacturing division of Gerresheimer with a complete line of regulatory compliant prescription containers for medication dispensing, packaging for robotic automation and standard and custom imprinted closures. At Centor, he oversaw significant revenue growth that led their company to achieve a market leading position in the prescription container and medication dispensing product segment. Additionally, Mr. Scheu served as COO of The Waddington Group, a division of Newell Brands (an $850 million per year disposable packaging manufacturer), President of B+H North America (a $400 million per year division of the AptarGroup), President of Rigid Closed Top (an ~$1 billion per year division of Berry Plastics Corporation), and executive sales and marketing roles at leading specialty market corporations. Mr. Scheu will be instrumental in leading Sharps’ marketing initiatives as the Company advances from research and development to commercial revenue. His initial focus will be leading sales efforts around Sharps’ commercial-ready Securegard®, a disposable smart safety syringe product offering with multiple configurations. Mr. Scheu will lead the efforts around commercialization and contracts with customers within the retail pharmacy space to support the efforts around the introduction of Sharps’ technology to healthcare customers, which include hospital networks. Sharps recently announced a qualification agreement with a major medical device company for its smart safety syringe technology that could drive increased commercial revenue in 2023. The agreement will begin with the 1mL and 3mL Securegard® product line and will be followed by Sologard® Luer lock syringes for larger volume drug applications. The qualification agreement will allow for the opportunity to create secondary sales agreements with additional key hospital networks, which Mr. Scheu will oversee. In conjunction with the vial-draw product launch, Sharps is also preparing for the commercialization of its next-generation polymer-based prefilled syringe systems, which will be the Company’s future growth driver. Technical and commercial resources will be added to Mr. Scheu’s prefilled product team, and Sharps will begin manufacturing from the Inject-EZ facility in Columbia, South Carolina. Through Mr. Scheu’s deep expertise in plastics operations and sales, he will play an integral role in supporting the partnership with Nephron Pharmaceuticals.
New Risk • Jun 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.87m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.87m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding).
お知らせ • Feb 07Sharps Technology, Inc. announced that it has received $3.8 million in fundingOn February 6, 2023, Sharps Technology, Inc. closed the transaction.
お知らせ • Feb 02Sharps Technology, Inc. announced that it expects to receive $3.8 million in fundingSharps Technology, Inc. announced that it has raised $3.8 million. The Company will issue 2,248,521 units and pre-funded units at a purchase price of $1.69 per unit priced at-the-market under Nasdaq rules.The pre-funded units will be sold at the same price less the pre-funded warrant exercise price of $0.001. Each unit and pre-funded unit consist of one share of common stock (or pre-funded warrant) and one non-tradable warrant exercisable for one share of common stock at a price of $1.56. The warrants have a term of five years from the issuance date. Gross proceeds were $3.8 million before deducting fees to the placement agent and other offering expenses payable by the Company. The transaction is expected to close on or about February 3, 2023
お知らせ • Feb 01Sharps Technology, Inc. Ships First Containers of Safety Syringes to Nephron Pharmaceuticals for CommercializationSharps Technology, Inc. announced the first shipments of product from its wholly owned manufacturing facility in Hungary to Nephron Pharmaceuticals to advance the Company's first commercial operations. Securegard is the first product that will be available to the market through the Company's collaboration with Nephron and will be introduced through Nephron’s network of more than 3,000 customers. Securegard is a vial draw product with innovative product features for safety, ultra-low waste and non-reuse that has been approved by the Food and Drug Administration (FDA), the World Health Organization (WHO), and received a CE Mark, facilitating global sales. Initial shipments will total 1.3 million 1-mililiter (1mL) units by February and will increase with additional volume and product configurations as sales commence.
お知らせ • Jan 12Sharps Technology Inc. to Introduces New Specialized Prefillable Syringe Systems in 2023Sharps Technology, Inc. announces the advancement of the Company's specialized prefillable syringe ("PFS") system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina. Sharps' specialized product pipeline and market strategy will include a broad range of sizes, silicon free systems that address contamination issues for the broader healthcare market, dual chamber systems that improve drug shelf life while reducing unnecessary packaging, and customized solutions for systems that serve the growing autoinjector segment. Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina. Initial demand will be supported by manufacturing capacity of 20+ million units, with additional capacities that can be scaled by 2025 with an additional 100 million units annually. Products will be manufactured utilizing Injection molding technologies with highly automated assembly lines. The products will be sterilized using an ecofriendly clean sterilization option easily adaptable for the pharmaceutical market. Sharps' PFS systems will utilize ISO Standard Nest and Tubs that will be compatible with existing fill-finish technologies to provide a drop-in solution for the industry.
Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jul 15Sharps Technology, Inc. (NasdaqCM:STSS) completed the acquisition of Safegard Medical (Hungary) Kft. from Numan Holding Ltd.Sharps Technology, Inc. (NasdaqCM:STSS) agreed to acquire Safegard Medical (Hungary) Kft. from Numan Holding Ltd. for $2.5 million on July 8, 2022. The purchase price of $2.5 million was released to Numan. Sharps Technology previously issued 28,571 shares of common stock and 35,714 warrants to purchase common stock at $7.00 per share to Numan. The Acquisition consisted primarily of Safegard’s syringe manufacturing facility in Hungary and the land on which it is located, as well as certain equipment in the facility. Sharps Technology, Inc. (NasdaqCM:STSS) completed the acquisition of Safegard Medical (Hungary) Kft. from Numan Holding Ltd. on July 14, 2022.
Board Change • Jun 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • May 13Independent Non-Executive Director recently bought US$140k worth of stockOn the 9th of May, Timothy Ruemler bought around 112k shares on-market at roughly US$1.25 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$263k more in shares than they have sold in the last 12 months.
Board Change • May 02High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 20Brenda Baird Simpson and Jason Monroe Elects to Sharps Technology, Inc.'s Board of DirectorsOn April 15, 2022, Brenda Baird Simpson and Jason Monroe were elected to the Sharps Technology, Inc.'s board of directors. Ms. Simpson will serve on the audit committee of the Company’s board of directors, and Mr. Monroe will serve on the audit, compensation and nominating committees.
お知らせ • Apr 16Sharps Technology, Inc. has completed an IPO in the amount of $15.9375 million.Sharps Technology, Inc. has completed an IPO in the amount of $15.9375 million. Security Name: Common Units Security Type: Equity/Derivative Unit Securities Offered: 3,750,000 Price\Range: $4.25 Discount Per Security: $0.34